# An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

> **NCT00591565** · NA · COMPLETED · sponsor: **State University of New York - Upstate Medical University** · enrollment: 13 (actual)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Acamprosate

## Key facts

- **NCT ID:** NCT00591565
- **Lead sponsor:** State University of New York - Upstate Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00591565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00591565, "An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00591565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*